Clinical trials: Chronic Obstruct Airways Disease
COPD
Phase II Clinical Study to Evaluate the Efficacy and Safety of XKH001 Injection
This is a multicenter, randomized, double-blind, placebo-parallel-controlled, two-stage design, Phase II clinical study. This study is divided into two stages.
- Trial name
- NCT07519499
- Testing
- XKH001Injection
- Volunteers
- 75 people
- Sponsor
- Zhejiang Kanova Biopharmaceutical Co., LTD
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)
To obtain further information on the prescribing pattern and therapeutic long term value in patients suffering from moderate or severs Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Trial name
- NCT02238184
- Testing
- Atrovent®, Ventilat®
- Volunteers
- 105 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
NVA237 Versus Placebo 12-week Efficacy Study
The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is efficient and safe.
- Trial name
- NCT01709864
- Testing
- NVA237
- Where
- 54 sites in United States
- Volunteers
- 440 people
- Sponsor
- Novartis Pharmaceuticals
COPD
Effects of Ergometer Training With Telemonitoring in Patients With Chronic Obstructive Pulmonary Disease (COPD) After Exacerbation
Home ergometer training combined with online monitoring and regular telephone support could prove to be a cost-effective method to improve physical performance and quality of life in COPD patients.
- Trial name
- COPD (NCT01987544)
- Testing
- Ergometer Training, Motivation
- Where
- Germany
- Volunteers
- 53 people
- Sponsor
- Institut für Pneumologie Hagen Ambrock eV
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)
This study is evaluating the effectiveness of a dose counter for an inhaler device used to deliver medication to people diagnosed with asthma or COPD.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
- Trial name
- NCT01302587
- Testing
- Albuterol
- Where
- 25 sites in United States
- Volunteers
- 306 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Obstructive Pulmonary Disease
Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to demonstrate equivalent efficacy between two different formulations of formoterol (pMDI using HFA-134 propellant and dry powder) on lung function in adult patients with partially reversible COPD.
- Trial name
- NCT00742248
- Testing
- Formoterol
- Where
- Italy
- Volunteers
- 54 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Emphysema
Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation
The purpose of this study is to determine the effective dose of the Aeris BLVR System in patients with advanced emphysema.
- Trial name
- NCT00205920
- Testing
- BLVR Hydrogel
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Aeris Therapeutics
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study was to assess the effect of CK-2127107 relative to placebo on cycle ergometer exercise tolerance, assessed as change from period baseline in constant work rate (CWR) endurance time, utilizing a…
- Trial name
- NCT02662582
- Testing
- Reldesemtiv
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Astellas Pharma Global Development, Inc.
COPD, Pulmonary Disease, Chronic Obstructive
A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
The purpose of this long-term observational study is designed to collect additional information on incidence of cancer and cause of death among patients who have participated in clinical trials of infliximab in the treatment of…
- Trial name
- NCT00380796
- Testing
- Collection of safety data for Cohort 1
- Where
- 26 sites in United States
- Volunteers
- 88 people
- Sponsor
- Centocor, Inc.
COPD
Predictive Questionnaires for Risk of Acute COPD (Chronic Obstructive Pulmonary Disease) Exacerbations
COPD patients frequently suffer intermittent exacerbations of their disease characterised by acute deterioration of symptoms. Acute exacerbations of COPD (AECOPD) are associated with significant impairment of health status, use…
- Trial name
- NCT01248507
- Where
- Spain
- Volunteers
- 634 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Effect of Indacaterol on Inspiratory Capacity (IC)
This study is being conducted to assess the effect of indacaterol (150 μg o.d.) on inspiratory capacity (IC), using placebo and open label tiotropium (18 μg o.d.) as comparators in patients with moderate chronic obstructive…
- Trial name
- NCT01012765
- Testing
- Indacaterol, Tiotropium
- Where
- 21 sites in Germany
- Volunteers
- 173 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD
The purpose of this study is to assess if 12 weeks' treatment with GSK573719 Inhalation Powder is safe and effective compared with placebo or no active drug intake, when administered once-daily in subjects with Chronic…
- Trial name
- NCT01387230
- Testing
- GSK573719
- Where
- 27 sites in United States, Germany and 1 more
- Volunteers
- 206 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).
This study will investigate the effect of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) metered dose inhaler (MDI) compared with Placebo MDI, and Budesonide and Formoterol Fumarate (BFF) MDI on isotime inspiratory…
- Trial name
- ATHLOS (NCT06067828)
- Testing
- Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 171 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population
The objective of this study was to examine COPD-related outcomes for patients with comorbid depression/anxiety who are on combination fluticasone propionate/salmeterol xinafoate compared to those receiving anticholinergics.
- Trial name
- NCT01337336
- Testing
- fluticasone propionate/salmeterol xinafoate, Anticholinergics
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease
This is a Phase III multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of two doses of GSK573719/GW642444 Inhalation Powder and GW642444 Inhalation Powder via a Novel Dry…
- Trial name
- NCT01316900
- Testing
- GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GW642444
- Where
- 97 sites in United States, France and 8 more
- Volunteers
- 846 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.
This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times.
- Trial name
- NCT00144911
- Testing
- Salmeterol, Fluticasone Propionate/Salmeterol Combination Product
- Where
- 97 sites in United States, Canada
- Volunteers
- 740 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Study to Investigate How Safe and Well Tolerated RV568 is in Patients With Chronic Obstructive Pulmonary Disease (COPD)
RV568 is being developed as a possible treatment of diseases such as smoking related lung disease (also known as Chronic Obstructive Pulmonary Disease - COPD) and asthma.
- Trial name
- NCT01475292
- Testing
- RV568
- Where
- 2 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Respivert Ltd
Chronic Obstructive Pulmonary Disease
A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo
A study to assess the safety, tolerability and efficacy of NVA237 versus placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
- Trial name
- GLOW 1 (NCT01005901)
- Testing
- Glycopyrronium bromide
- Where
- 96 sites in United States, Australia and 9 more
- Volunteers
- 1,324 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler
Open-label observational study which includes COPD patients that are receiving treatment with Spiolto® Respimat® for approximately 6 weeks, which is the average time between two medical consultations.
- Trial name
- NCT03663569
- Testing
- Spiolto® Respimat®
- Where
- 388 sites in Bulgaria, Czechia and 9 more
- Volunteers
- 4,819 people
- Sponsor
- Boehringer Ingelheim
COPD
A Six Month Randomized Controlled Clinical Trial of Lung Flute in Patients With Chronic Obstructive Pulmonary Disease
This is a 26 week randomized controlled study. The study consists of, in order, an enrollment visit, followed by clinic visits at 2 weeks, 14 weeks and at 26 weeks.
- Trial name
- NCT01186822
- Testing
- Lung Flute
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Nicolaas J Smit PhD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.